Skip to main content
SpringerLink
Log in

Immunology of Ocular Tumors

  • Chapter
  • First Online:
Book cover Clinical Ophthalmic Oncology

  • 1031 Accesses

Abstract

Understanding the fundamental immunological processes that play a role in tumor development will help us to better understand how to develop safe and efficient immune intervention strategies against ocular tumors and their metastases. Antitumor immune responses by T cells and antibodies may limit tumor growth, while on the other hand, the presence of tumor-infiltrating leukocytes may lead to the production of cytokines that stimulate tumor growth. In addition, environmental factors may have an influence on the tumor, as may aging, because aging is associated with a phenomenon known as para-inflammation, which is a local increase in infiltrating leukocytes and cytokines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3:879–89.

    Article  PubMed  CAS  Google Scholar 

  2. Ksander BR, Rubsamen PE, Olsen KR, Cousins SW, Streilein JW. Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. Invest Ophthalmol Vis Sci. 1991;32:3198–208.

    PubMed  CAS  Google Scholar 

  3. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599–602.

    Article  PubMed  Google Scholar 

  4. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res. 2009;28:348–68.

    Article  PubMed  Google Scholar 

  5. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.

    Article  PubMed  CAS  Google Scholar 

  6. Jensen OA, Andersen SR. Spontaneous regression of a malignant melanoma of the choroid. Acta Ophthalmol (Copenh). 1974;52:173–82.

    Article  CAS  Google Scholar 

  7. Reese AB, Archila EA, Jones IS, Cooper WC. Necrosis of malignant melanoma of the choroid. Am J Ophthalmol. 1970;69:91–104.

    PubMed  CAS  Google Scholar 

  8. Cochran AJ, Foulds WS, Damato BE, Trope GE, Morrison L, Lee WR. Assessment of immunological techniques in the diagnosis and prognosis of ocular malignant melanoma. Br J Ophthalmol. 1985;69:171–6.

    Article  PubMed  CAS  Google Scholar 

  9. Kan-Mitchell J, Liggett PE, Harel W, et al. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol Immunother. 1991;33:333–40.

    Article  PubMed  CAS  Google Scholar 

  10. Huang XQ, Mitchell MS, Liggett PE, Murphree AL, Kan-Mitchell J. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol Immunother. 1994;38:399–405.

    PubMed  CAS  Google Scholar 

  11. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, Murray TG. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. Curr Eye Res. 1998;17:165–73.

    Article  PubMed  CAS  Google Scholar 

  12. van der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002;188:51–64.

    Article  Google Scholar 

  13. Mulcahy KA, Rimoldi D, Brasseur F, et al. Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer. 1996;66:738–42.

    Article  PubMed  CAS  Google Scholar 

  14. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997;15:509–18.

    Article  PubMed  CAS  Google Scholar 

  15. Saba J, McIntyre CA, Rees RC, Murray AK. Recognition of melanoma-associated peptides by peripheral blood mononuclear cells of ocular melanoma patients. Adv Exp Med Biol. 1998;451:241–4.

    Article  PubMed  CAS  Google Scholar 

  16. Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38:1865–72.

    PubMed  CAS  Google Scholar 

  17. De Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1996;234:34–42.

    Article  PubMed  Google Scholar 

  18. Hurks HM, Metzelaar-Blok JA, Mulder A, Claas FH, Jager MJ. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. Int J Cancer. 2000;85:697–702.

    Article  PubMed  CAS  Google Scholar 

  19. Ericsson C, Seregard S, Bartolazzi A, et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:2153–6.

    PubMed  CAS  Google Scholar 

  20. Krishnakumar S, Abhyankar D, Lakshmi SA, Shanmugam MP, Pushparaj V, Biswas J. HLA class II antigen expression in uveal melanoma: correlation with clinicopathological features. Exp Eye Res. 2003;77:175–80.

    Article  PubMed  CAS  Google Scholar 

  21. Ma D, Luyten GP, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995;36:435–41.

    PubMed  CAS  Google Scholar 

  22. Ma D, Niederkorn JY. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995;86:263–9.

    PubMed  CAS  Google Scholar 

  23. Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol. 2002;63:444–51.

    Article  PubMed  CAS  Google Scholar 

  24. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol. 2000;165:710–5.

    PubMed  CAS  Google Scholar 

  25. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160:5693–6.

    PubMed  CAS  Google Scholar 

  26. Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci. 1990;31:2106–10.

    PubMed  CAS  Google Scholar 

  27. de la Cruz Jr PO, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112–5.

    Article  PubMed  Google Scholar 

  28. Whelchel JC, Farah SE, McLean IW, Burnier MN. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993;34:2603–6.

    PubMed  CAS  Google Scholar 

  29. Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53:5370–8.

    Article  PubMed  CAS  Google Scholar 

  30. Mougiakakos D, Johansson CC, Trocme E, et al. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer. 2010;116:2224–33.

    PubMed  Google Scholar 

  31. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:505–10.

    Article  PubMed  Google Scholar 

  32. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414–21.

    PubMed  CAS  Google Scholar 

  33. Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011;52:643–50.

    Article  PubMed  Google Scholar 

  34. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci. 2004;45:1–6.

    Article  PubMed  Google Scholar 

  35. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.

    Article  PubMed  CAS  Google Scholar 

  36. Bronkhorst IH, Jager MJ. Uveal melanoma: the inflammatory microenvironment. J Innate Immun. 2012;4:454–62.

    Article  PubMed  CAS  Google Scholar 

  37. Vu TH, Bronkhorst IH, Versluis M, et al. Analysis of inflammatory cells in uveal melanoma after prior irradiation. Invest Ophthalmol Vis Sci. 2013;54:360–9.

    Article  PubMed  CAS  Google Scholar 

  38. Leyvraz S, Keilholz U. Ocular melanoma: what’s new? Curr Opin Oncol. 2012;24:162–9.

    Article  PubMed  CAS  Google Scholar 

  39. Sapoznik S, Hammer O, Ortenberg R, et al. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol. 2012;2012:818214.

    Article  PubMed  Google Scholar 

  40. Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41–8.

    Article  PubMed  CAS  Google Scholar 

  41. Khattak MA, Fisher R, Hughes P, Gore M, Larkin J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res. 2013;23:79–81.

    Article  PubMed  CAS  Google Scholar 

  42. Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008;49:2518–25.

    Article  PubMed  Google Scholar 

  43. Richtig E, Langmann G, Schlemmer G, et al. Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma. Ophthalmologe. 2006;103:506–11.

    Article  PubMed  CAS  Google Scholar 

  44. de Vries IJ, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005;23:5779–87.

    Article  PubMed  Google Scholar 

  45. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.

    Article  PubMed  CAS  Google Scholar 

  46. Abdel-Rahman MH, Cebulla CM, Verma V, et al. Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res. 2012;100:26–31.

    Article  PubMed  CAS  Google Scholar 

  47. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670–7.

    Article  PubMed  CAS  Google Scholar 

  48. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011;71:5601–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Leiden University Medical Center (LUMC), 9600, 2300 RC, Leiden, The Netherlands

    Martine J. Jager & Inge H. G. Bronkhorst

Authors
  1. Martine J. Jager
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inge H. G. Bronkhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martine J. Jager .

Editor information

Editors and Affiliations

  1. Dept. of Ophthalmic Oncology, Cole Eye Institute Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Arun D. Singh

  2. Ocular Oncology Service, Dept. of Ophthalmol., University of California, San Francisco, San Francisco, California, USA

    Bertil Damato

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jager, M.J., Bronkhorst, I.H.G. (2014). Immunology of Ocular Tumors. In: Singh, A., Damato, B. (eds) Clinical Ophthalmic Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40489-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-40489-4_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-40488-7

  • Online ISBN: 978-3-642-40489-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation